Business
Aerska Launches with $21 Million in Financing to Develop RNAi Medicines for Diseases of the Brain
Seasoned RNAi and CNS leaders come together to build a pipeline of systemically administered RNA medicines using advances in ‘brain shuttles’ DUBLIN and LONDON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aerska, a biotechnology company aiming to redefine the treatment of neurological diseases, today announced it has raised $21 million in seed financing, co-led by Age1, Backed VC and Speedinvest, with participation from Blueyard, Lingotto (Exor), Norrsken VC, Kerna, PsyMed, Saras, and Ada Ventures. The co
About this update from Exor N.v.
[{"type":"image","alt":"Aerska","displaySize":"","headline":null,"caption":"Aerska","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":78,"url":"https://media.zenfs.com/en/globenewswire.com/891de0e864fbdcd52aa2e0abecf323d6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1BppVmbGoAOcgL46BX_Tyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/891de0e864fbdcd52aa2e0abecf323d6","width":300,"height":78}},"lazy":false},{"type":"text","content":"Seasoned RNAi and CNS leaders come together to build a pipeline of systemically administered RNA medicines using advances in ‘brain shuttles’","length":141,"tagName":"p"},{"type":"image","alt":"Photo credit: Aerska","displaySize":"","headline":null,"caption":"Photo credit: Aerska","className":"","disableSlideshowImg":false,"size":{"original":{"width":2250,"height":1501,"url":"https://media.zenfs.com/en/globenewswire.com/d7187cd5c14697debaeff52ec5117838"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a56vTQx7AKalzk768bpBfQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d7187cd5c14697debaeff52ec5117838","width":960,"height":640},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/oTAZbIP2QEDXPoiNJyQ6yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNjAyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d7187cd5c14697debaeff52ec5117838","width":1200,"height":801}}},{"type":"text","content":"DUBLIN and LONDON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aerska, a biotechnology company aiming to redefine the treatment of neurological diseases, today announced it has raised $21 million in seed financing, co-led by Age1, Backed VC and Speedinvest, with participation from Blueyard, Lingotto (Exor), Norrsken VC, Kerna, PsyMed, Saras, and Ada Ventures. The company is developing systemically administered RNA interference (RNAi) medicines designed to silence genes that drive brain diseases.","length":490,"tagName":"p"},{"type":"text","content":"Delivering genetic medicines to the brain has long been hindered by the blood-brain barrier. While RNAi has proven effective in the liver, its potential impact in the CNS has been limited by delivery. Through external partnerships and internal innovation, Aerska’s antibody-oligo conjugate (AOC) platform uses “brain shuttles” to enable systemic RNAi delivery, neuron...